high5immunology.tv | IBD | UEG Week 2021

Most viewed UEG week 2021

100 seconds

UEG 2021

Where is the future in IBD treatment? P19, JAKi, S1P?

Peter Irving, MD

UEG 2021

Is STRIDE II already history?

F. Gomollón, P. Eder, S. Schreiber, P. Irving

100 seconds

UEG 2021

UEG highlights: Vedolizumab in Chronic pouchitis; …

Silvio Danese, MD

100 seconds

UEG 2021

IL-23: Risankizumab - effective maintenance, long carry…

Stefan Schreiber, MD

UEG 2021

Side Effects - Biologicals: News from UEGw

F. Gomollón, P. Eder, S. Schreiber, P. Irving

post UEG Team Discussion

UEG 2021

What's the right target? JAK1 or JAK3 or TYK2?

A. Dignaß, A. Magro, M. C. Fantini, S. Danese, S. Schreiber

UEG 2021

Discontinuation strategies: Data hint towards…

Piotr Eder, Md, PhD

UEG 2021

How to significantly reduce the arterial vascular risk…

David Laharie, MD

100 seconds

UEG 2021

STRIDE 2.0 - Treatment goals in IBD: Patient…

Axel Dignaß, MD

100 seconds

UEG 2021

Single JAK targeting: JAK1 vs. JAK3

Stefan Schreiber, MD

100 seconds

UEG 2021

A panoramic view of UEG and IBD from Spain

Fernando Gomollón, MD

Spotlight Discussions – Targeting Efficacy

post UEG Team Discussion

UEG 2021

Do we need IL-23 blockade? Are all inhibitors the same?

A. Dignaß, F. Gomollón, F. Magro, M.C. Fantini, S. Danese, S. Schreiber

UEG 2021

Treatment targets: The impact of STRIDE II on our…

G. Mantzaris, I. Dotan, M. Allez, A. Dignaß, S. Schreiber

post UEG Team Discussion

UEG 2021

What's the right target? JAK1 or JAK3 or TYK2?

A. Dignaß, A. Magro, M. C. Fantini, S. Danese, S. Schreiber

UEG 2021

Do we need H2H trials? We need new endpoints, regaining…

G. Mantzaris, I. Dotan, M. Allez, A. Dignaß

post UEG Team Discussion

UEG 2021

Review JAK1 Inhibition: great speed of action,…

A. Dignaß, F.Magro, M. C. Fantini, S. Danese, S. Schreiber

post UEG Team Discussion

UEG 2021

Targeting S1P: effective, well tolerated, soon to be…

A. Dignaß, F. Gomollón, F. Magro, M.C. Fantini, S. Danese, S. Schreiber

post UEG Team Discussion

UEG 2021

What do drug levels and antibody levels tell us?

A. Dignaß, F. Magro, M. C. Fantini, S. Danese, S. Schreiber

Targeting Efficacy in 100 seconds – ENG

100 seconds

UEG 2021

UEG highlights: Vedolizumab in Chronic pouchitis; …

Silvio Danese, MD

100 seconds

UEG 2021

Dose escalation strategies to increase the efficacy of…

Johan Burisch, MD

100 seconds

UEG 2021

S1P targeting: very immediate effficacy and good safety…

Stefan Schreiber, MD

100 seconds

UEG 2021

Tofacitinib numerically increases Herp Zoster risk…

Fernando Magro, MD

100 seconds

UEG 2021

Upadacitinib with rapid and effective control of…

Fernando Magro, MD

100 seconds

UEG 2021

IL-23: Risankizumab - effective maintenance, long carry…

Stefan Schreiber, MD

100 seconds

UEG 2021

Single JAK targeting: JAK1 vs. JAK3

Stefan Schreiber, MD

Targeting Efficacy in 100 seconds – ITA/ GER / DK

100 seconds

UEG 2021

UEG highlights: Vedolizumab in Chronic pouchitis; …

Silvio Danese, MD

100 seconds

UEG 2021

Risankizumab: Effektive Erhaltung mit Langzeiteffekt

Stefan Schreiber, MD

100 seconds

UEG 2021

JAK1 vs. JAK3 - was ist effektiver?

Stefan Schreiber, MD

100 seconds

UEG 2021

Neue JAK-Therapieoptionen vor der Zulassung. Es wird…

Axel Dignaß, MD

100 seconds

UEG 2021

Dose escalation strategies to increase the efficacy of…

Johan Burisch, MD

100 seconds

UEG 2021

S1P Rezeptor Agonisten mit unmittelbarer Effektivität…

Stefan Schreiber, MD

Spotlight Discussions – Targeting Safety

UEG 2021

Immunosuppression and COVID: vaccination is effective,…

G. Mantzaris, I. Dotan, M. Allez, A. Dignaß, S. Schreiber

UEG 2021

Side Effects - Oral Therapies: News from UEGw

F. Gomollón, P. Eder, S. Schreiber

UEG 2021

Side Effects - Biologicals: News from UEGw

F. Gomollón, P. Eder, S. Schreiber, P. Irving

Targeting Safety in 100 seconds – ENG

100 seconds

UEG 2021

Safety of Ustekinumab in elderly patients - no…

Piotr Eder, MD, PhD

100 seconds

UEG 2021

Protein profiling as efficacy predictor of infliximab…

Johan Burisch, MD

100 seconds

UEG 2021

How to significantly reduce the arterial vascular risk…

David Laharie, MD

Targeting Safety in 100 seconds – POL/FRA/DEN

100 seconds

UEG 2021

Protein profiling as efficacy predictor of infliximab…

Johan Burisch, MD

100 seconds

ACR 2021

IBD w wieku podeszłym - czy można bezpiecznie stosować…

Piotr Eder, MD, PhD

100 seconds

UEG 2021

Comment réduire le risque cardio-vasculaire associé aux…

David Laharie, MD

Spotlight Discussions – Therapy concepts

UEG 2021

Is STRIDE II already history?

F. Gomollón, P. Eder, S. Schreiber, P. Irving

UEG 2021

What ist the most exciting new drug on the horizon?…

F. Gomollón, P. Eder, S. Schreiber, P. Irving

UEG 2021

Microbiome, nutrition and life style: The effect on…

G. Mantzaris, I. Dotan, M. Allez, A. Dignaß

UEG 2021

Disease Clearance in UC: How can we translate this into…

G. Mantzaris, I. Dotan, M. Allez, A. Dignaß

post UEG Team Discussion

UEG 2021

Disease clearance? Treat to target still correct?

A. Dignaß, F. Gomollón, F. Magro, M.C. Fantini, S. Danese, S. Schreiber

Therapy Concepts in 100 Seconds – ENG

100 seconds

UEG 2021

PK SEAVUE Study: high proportion of patients with…

Fernando Magro, MD

100 seconds

UEG 2021

Risankizumab: 12 weeks induction in patients wo initial…

Fernando Magro, MD

100 seconds

UEG 2021

Discontinuation strategies: Data hint towards…

Piotr Eder, Md, PhD

100 seconds

UEG 2021

Do not stop infliximab in patients in complete…

David Laharie, MD

100 seconds

UEG 2021

SEAVUE PK update: Immunogenicity of Ustekinumab vs…

Massimo Claudio Fantini, MD, PhD

Therapy Concepts in 100 Seconds – POL/ITA/FRA

100 seconds

UEG 2021

Czy warto kończyć terapię IFX w przypadku głębokiej…

Piot Eder, MD, PhD

100 seconds

UEG 2021

Ustekinumab e Adalimumab: farmacocinetica e…

Massimo Claudio Fantini, MD, PhD

100 seconds

UEG 2021

Mieux vaut ne pas arrêter l’infliximab dans la maladie…

David Laharie, MD

Treatment goals in 100 Seconds – ENG

100 seconds

UEG 2021

STRIDE 2.0 - Treatment goals in IBD: Patient…

Axel Dignaß, MD

100 seconds

UEG 2021

JAK inhibitors showing quick response in PRO…

Massimo Claudio Fantini, MD, PhD

100 seconds

UEG 2021

Disease Clearance the future therapeutic goal…

Axel Dignaß, MD

Treatment goals in 100 Seconds – GER/ITA

100 seconds

UEG 2021

JAK inhibitors e rapidità nel miglioramento dei PROs: i…

Massimo Claudio Fantini, MD, PhD

100 seconds

UEG 2021

Therapieziele: Disease Clearance bei der Colitis…

Axel Dignaß, MD

100 seconds

UEG 2021

Therapieziele - STRIDE 2.0: Die Patientenperspektive,…

Axel Dignaß, MD

New treatment concepts in 100 seconds – ENG

100 seconds

UEG 2021

Vedolizumab effective in resistant pouchitis

Peter Irving, MD

100 seconds

UEG 2021

UEG highlights: Vedolizumab in Chronic pouchitis; …

Silvio Danese, MD

100 seconds

UEG 2021

Ritlecitinib & Brepocitinib good remission rates and…

Massimo Claudio Fantini, MD, PhD

100 seconds

UEG 2021

New treatment options about to be approved. Treatment…

Axel Dignaß, MD

100 seconds

UEG 2021

New treatment options: IL23 modulators Risankizumab and…

Axel Dignaß, MD

New treatment concepts in 100 seconds – GER/ITA

UEG 2021

Ritlecitinib e Prebocitinib i nuovi arrivati nel mondo…

Massimo Claudio Fantini, MD, PhD

100 seconds

UEG 2021

UEG highlights: Vedolizumab in Chronic pouchitis; …

Silvio Danese, MD

100 seconds

UEG 2021

Neue Therapieoptionen: IL23 Modulation durch…

Axel Dignaß. MD

UEG Week in 100 seconds – ENG

100 seconds

UEG 2021

UEG highlights: Vedolizumab in Chronic pouchitis; …

Silvio Danese, MD

100 seconds

UEG 2021

Where is the future in IBD treatment? P19, JAKi, S1P?

Peter Irving, MD

100 seconds

UEG 2021

A panoramic view of UEG and IBD from Spain

Fernando Gomollón, MD

100 seconds

UEG 2021

Spanish IBD contributions to UEGW: more and more…

Fernando Gomollón, MD

100 seconds

UEG 2021

No assocation between COVID outcome and IBD therapy

Johan Burisch, MD

UEG Week in 100 seconds – ESP/ITA/DEN

100 seconds

UEG 2021

Aportación española a la UEGW en EII: más y mejor

Fernando Gomollón, MD

100 seconds

UEG 2021

No assocation between COVID outcome and IBD therapy

Johan Burisch, MD

100 seconds

UEG 2021

UEG highlights: Vedolizumab in Chronic pouchitis; …

Silvio Danese, MD

100 seconds

UEG 2021

Un visión panorámica de la UEG y la EII desde España

Fernando Gomollón, MD